KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Notes Payables (2016)

Historic Notes Payables for Bristol Myers Squibb (BMY) over the last 8 years, with Q2 2016 value amounting to $155.0 million.

  • Bristol Myers Squibb's Notes Payables fell 7947.02% to $155.0 million in Q2 2016 from the same period last year, while for Jun 2016 it was $155.0 million, marking a year-over-year decrease of 7947.02%. This contributed to the annual value of $139.0 million for FY2015, which is 7644.07% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported Notes Payables of $155.0 million as of Q2 2016, which was down 7947.02% from $106.0 million recorded in Q1 2016.
  • Over the past 5 years, Bristol Myers Squibb's Notes Payables peaked at $1.4 billion during Q1 2013, and registered a low of $106.0 million during Q1 2016.
  • Its 5-year average for Notes Payables is $494.3 million, with a median of $383.0 million in 2014.
  • Its Notes Payables has fluctuated over the past 5 years, first surged by 84620.69% in 2013, then tumbled by 7951.9% in 2014.
  • Bristol Myers Squibb's Notes Payables (Quarter) stood at $826.0 million in 2012, then tumbled by 56.54% to $359.0 million in 2013, then surged by 64.35% to $590.0 million in 2014, then plummeted by 76.44% to $139.0 million in 2015, then rose by 11.51% to $155.0 million in 2016.
  • Its last three reported values are $155.0 million in Q2 2016, $106.0 million for Q1 2016, and $139.0 million during Q4 2015.